Cent Raises $15M Series A, Buys AI Radiology Firm Medsee

Preventive healthcare startup Cent has raised $15 million in a Series A round co-led by Blume Ventures and South Park Commons, and simultaneously acquired Medsee, an AI-powered radiology platform, to sharpen its screening technology.

The round also drew individual checks from Arun Sarin, Srinivas Narayanan, Sharath Narayana, Aprameya Radhakrishna and Krishan Sridhar. Cent disclosed neither a valuation nor the Medsee purchase price.

Shashank ND, who previously founded healthcare platform Practo, built Cent to catch disease before symptoms show. The company combines medical imaging, biomarkers and AI analysis to flag health risks early — a bet that comprehensive screening beats the routine check-up's limited test menu.

What does the screening actually involve?

Cent compresses a full diagnostic workup into a single session of roughly two hours. The protocol includes:

• Full-body magnetic resonance imaging (MRI)
• Low-dose computed tomography (CT) scans
• Dual-energy X-ray absorptiometry (DEXA)
• Electrocardiograms (ECG)
• Echocardiograms (ECHO)
• More than 100 biomarkers

The company runs its own screening centres in Bengaluru, Mumbai and Delhi-NCR, and works with a network of partner diagnostic laboratories to extend reach.

How many people has Cent screened?

About 10,000 people have gone through Cent's protocol over the past year. According to the company, one in four of them had findings that required medical attention, and one in 40 needed an immediate consultation with a doctor.

Those hit rates are the core of Cent's pitch: surface silent conditions — tumors, cardiac faults, metabolic drift — while intervention is still cheap and outcomes are still good.

Where will the $15 million go?

Cent plans to deploy the fresh capital into medical hardware, AI capabilities, clinical research and broader technology infrastructure as it scales its preventive healthcare services.

The Medsee acquisition feeds directly into that plan. Medsee's AI radiology technology is intended to strengthen Cent's reporting process and help the company manage growing scan volumes — a real constraint once thousands of full-body MRIs start stacking up.

The company has set two long-term targets: 10 million scans conducted by 2035, and one million lives saved through early detection. Those are ambitious numbers for a startup that has screened 10,000 people to date, and they imply a thousandfold increase in throughput over the next decade.

Why now? India's diagnostic lag

Cent's expansion lands against a stark public health backdrop. India has approximately 101 million people living with diabetes and another 136 million with prediabetes, according to figures cited in the company's announcement. An estimated 315 million people in the country have hypertension.

Many noncommunicable diseases in India are diagnosed only after they have progressed, when treatment is costlier and survival rates are worse. Cent is positioning its imaging-plus-biomarkers-plus-AI stack as the gap-filler: find the risk early, route the patient to a doctor, change the trajectory.

The founder's second act

Shashank ND isn't walking away from his first company. In September 2026, Practo elevated him to managing director and executive chairman, while Jagnoor Singh took over as chief executive officer. Shashank ND is now building in healthcare on two fronts simultaneously.

With the Series A closed and Medsee in the fold, Cent's next test is operational: scale screening volumes across its three-city footprint while maintaining clinical quality and making early detection affordable enough to matter at population scale.

By Amara Osei